← All trials
NCT04998240
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2021
- Primary completion
- Oct 30, 2022
- Completion date
- Oct 30, 2022
- First posted
- Aug 10, 2021
- Last posted
- Aug 10, 2021
- Enrollment
- 360
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Vaccine InstituteLead sponsor
- Harvard UniversityCollaborator
- University of HeidelbergCollaborator
- International Center for Diarrheal Disease ResearchCollaborator
- International Vaccine InstituteOverall official - principal investigator
- Government of MozambiqueOverall official - principal investigator
- Government of MozambiqueCollaborator
- University of AntananarivoCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.